STOCK TITAN

Olema Pharmaceuticals, Inc. - $OLMA STOCK NEWS

Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: $OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Olema Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Olema Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.59%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.97%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.2%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.28%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.23%
Tags
Olema Pharmaceuticals, Inc.

Nasdaq:OLMA

OLMA Rankings

OLMA Stock Data

563.25M
28.47M
3.94%
96.27%
14.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO

About OLMA

olema oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. our lead program, op-1250, a potential best-in-class complete estrogen receptor antagonist (ceran), is in development to treat estrogen receptor-positive (er+), human epidermal growth factor receptor 2-negative (her2-) breast cancer. olema recently initiated a phase 1/2 dose-escalation and expansion clinical trial of op-1250. we are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. for more information about the company please visit www.olema.com.